-
Radezolid (INN,
codenamed RX-1741) is a
novel oxazolidinone antibiotic being developed by
Melinta Therapeutics, Inc. for the
treatment of
bacterial acne...
-
ractalind (INN)
ractopamine (INN)
radafaxine (USAN)
radavirsen (USAN)
radezolid (USAN, INN)
Radiogardase radotinib (INN)
radretumab (INN) rafivirumab...
- inhibitor;
prevents the
initiation step
Posizolid Phase II
clinical trials Radezolid Phase II
clinical trials Tedizolid Sivextro Penicillins Amoxicillin Novamox...
- antibiotics. Tedizolid, (Sivextro)
which is
approved for
acute skin
infections Radezolid (RX-1741) has
completed some phase-II
clinical trials.
Contezolid (MRX-I)...
- development, such as
posizolid (AZD2563),
ranbezolid (RBx 7644), and
radezolid (RX-1741). In 2014, the FDA
approved tedizolid phosphate, a second-generation...
- 2006, was
approved by the FDA in 2017. By 2016, the
company developed radezolid, a next-generation
oxazolidinone for
bacterial acne.
Melinta also markets...
-
Oxazolidinone (initiation inhibitors)
Eperezolid Linezolid#
Posizolid Radezolid Ranbezolid Sutezolid Tedizolid Peptidyl transferase MLS (transpeptidation/translocation)...
-
Oxazolidinone (initiation inhibitors)
Eperezolid Linezolid#
Posizolid Radezolid Ranbezolid Sutezolid Tedizolid Peptidyl transferase MLS (transpeptidation/translocation)...
